In Brief: Canada proposes nicotine patch switch
This article was originally published in The Tan Sheet
Executive Summary
Canada proposes nicotine patch switch: Health Canada Therapeutic Products Programme proposes switch of transdermal nicotine patches with delivery rates of 22 mg/day and less to nonprescription status in a regulatory amendment published in the July 19 Canada Gazette, Part I. Rx patches are marketed in Canada by Novartis, Hoechst Marion Roussel, Boerhinger Ingelheim and McNeil. TPP intends to proceed directly to the Canada Gazette, Part II if favorable comments are received, thereby quickening the switch process. OTC nicotine chewing gum in a 4 mg strength will be available "shortly," the notice states...